Objectif A large part of the data collected during the biomedical research is wasted, because there is no affordable and easy-to-use Electronic Data Capture (EDC) tool for clinical trials. As a result, 85% of the research investment in the biomedical research domain – equating to $200 billion – is dissipated. Castor is a disruptive EDC that solves this problem. It has been successfully commercialized to 5,000 users in the Netherlands, especially in the academic sector. In terms of price and functionalities, Castor EDC is tailored to the needs SMEs performing medical research (e.g. Commercial Research Organizations working on drug development and SMEs manufacturing medical devices/wearables) and academic institutions; these segments are neglected by the existing commercial EDC platforms, which mainly target the needs of pharmaceutical corporations. This market is enormous (over €1.7B globally) and growing quickly due to the recent EU regulations on sensitive data protection. Castor EDC is also the first EDC complying with the FAIR guidelines for data collection, which will become the standard de facto within a couple of years. Thanks to these characteristics, data sets can now be easily shared across researchers and reused, thus unlocking the potential of data of biomedical studies. This will help to overcome the current fragmentation of the European databases that has led to lost opportunities when making sense of big data in health research. This innovation project has two main objectives. First, upgrading the existing tool to TRL 9, by enhancing with advanced functionalities the Electronic Data Capture tool and integrate it with i) a platform that facilitates researchers in sharing and reusing their datasets and ii) a marketplace where 3rd party developers can offer additional services to work on those datasets. Second, carry out the planned exploitation activities to establish Castor EDC as a EU-28 market leader in the market within 3 years from the end of the project. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencescomputer and information sciencescomputer securitydata protectionmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural sciencescomputer and information sciencesdata sciencebig datasocial sciencessociologyindustrial relationsautomation Programme(s) H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Thème(s) SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-2-2016-2017 Régime de financement SME-2 - SME instrument phase 2 Coordinateur CIWIT BV Contribution nette de l'UE € 1 083 250,00 Adresse PAASHEUVELWEG 25 1105 BP AMSTERDAM Pays-Bas Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région West-Nederland Noord-Holland Groot-Amsterdam Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 1 547 500,00
